These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31109210)

  • 21. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
    Huber CM; Yee C; May T; Dhanala A; Mitchell CS
    J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives.
    Sun BL; Chen Y; Fan DY; Zhu C; Zeng F; Wang YJ
    Sci China Life Sci; 2021 Jun; 64(6):926-937. PubMed ID: 33106917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
    Reddy PH; Oliver DM
    Cells; 2019 May; 8(5):. PubMed ID: 31121890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.
    Zhang ZX; Zhao RP; Wang DS; Li YB
    Neurochem Res; 2016 Nov; 41(11):3074-3082. PubMed ID: 27518086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease.
    Li H; Wang X; Yu H; Zhu J; Jin H; Wang A; Yang Z
    Curr Neuropharmacol; 2018; 16(6):758-768. PubMed ID: 29086699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
    Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
    Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical to phase II amyloid beta (A
    Parsons CG; Rammes G
    Expert Opin Investig Drugs; 2017 May; 26(5):579-592. PubMed ID: 28362514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
    Takeda S
    Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease.
    Golde TE; Dickson D; Hutton M
    Curr Alzheimer Res; 2006 Dec; 3(5):421-30. PubMed ID: 17168641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.
    Wu XL; Piña-Crespo J; Zhang YW; Chen XC; Xu HX
    Chin Med J (Engl); 2017 Dec; 130(24):2978-2990. PubMed ID: 29237931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.